{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Fluticasone+propionate+250+mcg+BID",
    "query": {
      "intervention": "Fluticasone propionate 250 mcg BID"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 28,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Fluticasone+propionate+250+mcg+BID&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-01T15:44:36.527Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01323621",
      "title": "Study Evaluating the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "Fluticasone Furoate 100mcg/ GW642444 (vilanterol) 25mcg",
          "type": "DRUG"
        },
        {
          "name": "Fluticasone Propionate 250mcg / salmeterol 50mcg",
          "type": "DRUG"
        },
        {
          "name": "Double-dummy placebo",
          "type": "DRUG"
        },
        {
          "name": "Salbutamol as needed",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 512,
      "start_date": "2011-03-18",
      "completion_date": "2012-01-24",
      "has_results": true,
      "last_update_posted_date": "2018-02-15",
      "last_synced_at": "2026-10-01T15:44:36.527Z",
      "location_count": 13,
      "location_summary": "Jasper, Alabama • Riverside, California • DeLand, Florida + 10 more",
      "locations": [
        {
          "city": "Jasper",
          "state": "Alabama"
        },
        {
          "city": "Riverside",
          "state": "California"
        },
        {
          "city": "DeLand",
          "state": "Florida"
        },
        {
          "city": "Coeur d'Alene",
          "state": "Idaho"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01323621"
    },
    {
      "nct_id": "NCT01706328",
      "title": "A Study to Assess the Efficacy of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "FF/VI 100/25 Inhalation Powder NDPI",
          "type": "DRUG"
        },
        {
          "name": "Fluticasone Propionate/Salmeterol 250/50 Inhalation Powder ACCUHALER/DISKUS",
          "type": "DRUG"
        },
        {
          "name": "Placebo Inhalation Powder NDPI",
          "type": "DRUG"
        },
        {
          "name": "Placebo Inhalation Powder ACCUHALER/DISKUS",
          "type": "DRUG"
        },
        {
          "name": "Salbutamol as needed",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 828,
      "start_date": "2012-10-15",
      "completion_date": "2013-06-17",
      "has_results": true,
      "last_update_posted_date": "2018-05-02",
      "last_synced_at": "2026-10-01T15:44:36.527Z",
      "location_count": 16,
      "location_summary": "Clearwater, Florida • DeLand, Florida • Coeur d'Alene, Idaho + 13 more",
      "locations": [
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "DeLand",
          "state": "Florida"
        },
        {
          "city": "Coeur d'Alene",
          "state": "Idaho"
        },
        {
          "city": "Normal",
          "state": "Illinois"
        },
        {
          "city": "Woodbury",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01706328"
    },
    {
      "nct_id": "NCT00657774",
      "title": "A Phase I Study in Asthma Patients Evaluating the Effect of Doses of FlutiForm™ on the Amount, if Any, of Cortisol Produced by the Adrenal Glands",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "FlutiForm 250/10 ug",
          "type": "DRUG"
        },
        {
          "name": "FlutiForm 100/10 ug",
          "type": "DRUG"
        },
        {
          "name": "Oral Prednisone 10mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SkyePharma AG",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 160,
      "start_date": "2008-04",
      "completion_date": "2008-09",
      "has_results": false,
      "last_update_posted_date": "2008-12-01",
      "last_synced_at": "2026-10-01T15:44:36.527Z",
      "location_count": 19,
      "location_summary": "Phoenix, Arizona • Anaheim, California • Long Beach, California + 16 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Centennial",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00657774"
    },
    {
      "nct_id": "NCT00395304",
      "title": "Childhood Asthma Research and Education (CARE) Network Trial - Best Add-On Therapy Giving Effective Response (BADGER)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "fluticasone propionate + montelukast",
          "type": "DRUG"
        },
        {
          "name": "fluticasone propionate",
          "type": "DRUG"
        },
        {
          "name": "fluticasone propionate + salmeterol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Milton S. Hershey Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "6 Years to 18 Years"
      },
      "enrollment_count": 182,
      "start_date": "2007-03",
      "completion_date": "2011-12",
      "has_results": true,
      "last_update_posted_date": "2018-07-02",
      "last_synced_at": "2026-10-01T15:44:36.527Z",
      "location_count": 5,
      "location_summary": "Tucson, Arizona • San Diego, California • Denver, Colorado + 2 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00395304"
    },
    {
      "nct_id": "NCT02301975",
      "title": "An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol 100/25 Microgram (mcg) Inhalation Powder, Fluticasone Propionate/Salmeterol 250/50 mcg Inhalation Powder, and Fluticasone Propionate 250 mcg Inhalation Powder in Adults and Adolescents With Persistent Asthma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Fluticasone Furoate/Vilanterol 100/25 mcg via ELLIPTA inhaler",
          "type": "DRUG"
        },
        {
          "name": "Placebo inhalation powders via ELLIPTA inhaler",
          "type": "DRUG"
        },
        {
          "name": "Fluticasone Propionate/Salmeterol 250/50 mcg via ACCUHALER/DISKUS inhaler",
          "type": "DRUG"
        },
        {
          "name": "Placebo inhalation powder via ACCUHALER/DISKUS inhaler",
          "type": "DRUG"
        },
        {
          "name": "Fluticasone Propionate 250 mcg via ACCUHALER/DISKUS inhaler",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 1526,
      "start_date": "2015-03-01",
      "completion_date": "2016-11-25",
      "has_results": true,
      "last_update_posted_date": "2018-08-06",
      "last_synced_at": "2026-10-01T15:44:36.527Z",
      "location_count": 34,
      "location_summary": "Huntington Beach, California • Riverside, California • Rolling Hills Estates, California + 30 more",
      "locations": [
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Riverside",
          "state": "California"
        },
        {
          "city": "Rolling Hills Estates",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Upland",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02301975"
    },
    {
      "nct_id": "NCT00235053",
      "title": "Study to Assess the Incidence of Local Oropharyngeal and Laryngeal Adverse Effects of Advair DISKUS 250/50 mcg BID",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Asthma",
        "Candidiasis, Oral",
        "Voice Disorders"
      ],
      "interventions": [
        {
          "name": "fluticasone/salmeterol DISKUS 250/50",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergy & Asthma Medical Group & Research Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 13,
      "start_date": "2005-08",
      "completion_date": "2005-11",
      "has_results": false,
      "last_update_posted_date": "2024-01-30",
      "last_synced_at": "2026-10-01T15:44:36.527Z",
      "location_count": 1,
      "location_summary": "San Diego, California",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00235053"
    },
    {
      "nct_id": "NCT01537133",
      "title": "Airway Microbiome in Asthma: Relationships to Asthma Phenotype and Inhaled Corticosteroid Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Asthma",
        "Atopy"
      ],
      "interventions": [
        {
          "name": "fluticasone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Milton S. Hershey Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 84,
      "start_date": "2012-10",
      "completion_date": "2014-07",
      "has_results": true,
      "last_update_posted_date": "2016-11-30",
      "last_synced_at": "2026-10-01T15:44:36.527Z",
      "location_count": 9,
      "location_summary": "San Francisco, California • Denver, Colorado • Chicago, Illinois + 6 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01537133"
    },
    {
      "nct_id": "NCT00403286",
      "title": "A Dose-Finding Study Evaluating Safety and Efficacy in Patients With Chronic Obstructive Pulmonary Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease"
      ],
      "interventions": [
        {
          "name": "Fluticasone Propionate/Formoterol Fumarate",
          "type": "DRUG"
        },
        {
          "name": "Fluticasone Propionate",
          "type": "DRUG"
        },
        {
          "name": "Formoterol Fumarate",
          "type": "DRUG"
        },
        {
          "name": "Fluticasone Propionate/Salmeterol Xinafoate",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dey",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 457,
      "start_date": "2006-11",
      "completion_date": "2007-05",
      "has_results": false,
      "last_update_posted_date": "2009-06-30",
      "last_synced_at": "2026-10-01T15:44:36.527Z",
      "location_count": 49,
      "location_summary": "Birmingham, Alabama • Jasper, Alabama • Phoenix, Arizona + 44 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Jasper",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Buena Park",
          "state": "California"
        },
        {
          "city": "Costa Mesa",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00403286"
    },
    {
      "nct_id": "NCT01225913",
      "title": "Mechanism(s) of Airflow Limitation During Exacerbation of Asthma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "fluticasone/salmeterol in all asthmatics",
          "type": "DRUG"
        },
        {
          "name": "budesonide/formoterol or fluticasone/salmeterol in all asthmatics",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gelb, Arthur F., M.D.",
      "sponsor_class": "INDIV",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "10 Years to 80 Years"
      },
      "enrollment_count": 50,
      "start_date": "2007-10",
      "completion_date": "2027-06",
      "has_results": false,
      "last_update_posted_date": "2023-10-26",
      "last_synced_at": "2026-10-01T15:44:36.527Z",
      "location_count": 1,
      "location_summary": "Lakewood, California",
      "locations": [
        {
          "city": "Lakewood",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01225913"
    },
    {
      "nct_id": "NCT02593123",
      "title": "Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hodgkin's Lymphoma",
        "Lymphoid Leukemia",
        "Lymphoma",
        "Leukemia",
        "Myeloma",
        "Acute Lymphocytic Leukemia",
        "Non Hodgkin Lymphoma",
        "Chronic Lymphocytic Leukemia",
        "Multiple Myeloma",
        "Chronic Myelogenous Leukemia",
        "Myelodysplastic Syndromes",
        "Recurrent Acute Myeloid Leukemia, Adult",
        "Recurrent Hodgkin Lymphoma",
        "Recurrent Non-Hodgkin Lymphoma",
        "Recurrent Plasma Cell Myeloma",
        "Recurrent Chronic Lymphocytic Leukemia",
        "Recurrent Chronic Myelogenous Leukemia",
        "Acute Myelogenous Leukemia"
      ],
      "interventions": [
        {
          "name": "mycophenolate mofetil",
          "type": "DRUG"
        },
        {
          "name": "Sargramostim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Filgrastim",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Virginia Commonwealth University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "74 Years",
        "sex": "ALL",
        "summary": "18 Years to 74 Years"
      },
      "enrollment_count": 31,
      "start_date": "2015-11-04",
      "completion_date": "2022-03-18",
      "has_results": true,
      "last_update_posted_date": "2023-01-23",
      "last_synced_at": "2026-10-01T15:44:36.527Z",
      "location_count": 1,
      "location_summary": "Richmond, Virginia",
      "locations": [
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02593123"
    }
  ]
}